{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:07:26Z","timestamp":1794586046000,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The drive to vaccinate large populations is nowadays the main instrument for combating the pandemic and preventing serious disease and death. However, breakthrough infection (post-vaccination infection) still happens after vaccination among fully vaccinated people. We aimed to assess the severity outcomes and to determine its associated factors among vaccinated COVID-19 cases in the governorate of Sousse, Tunisia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We carried out a five-month observational longitudinal study including all the population of Sousse. Confirmed infections of SARS-CoV-2 and the vaccination status are recorded in the daily COVID- 19 database of the Regional Office of the Tunisian Ministry of Health. We included all post-vaccination COVID-19 cases for the analysis of the COVID-19 serious outcomes. Data were collected via 15-min telephonic call interviews conducted by trained interviewers. Descriptive analysis with calculating incidence rates of confirmed COVID-19 cases per 100,000 inhabitants was conducted. In binary logistic regression, adjusted odds ratios along with 95% intervals confidence were performed to determine factors related to severe or critical COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>As of 31 July 2021, 107,545 persons over 19\u00a0years old have received at least one dose of COVID-19 vaccination. Among the vaccinated population, we traced and included 765 breakthrough infection cases, and the incidence rate was 711.3 per week. The majority were female (sex-ratio\u2009=\u20090.8), and the average age of the overall cases was 55.7\u00a0years. The prevalence of severe or critical cases in vaccinated COVID-19 patients occurs in 10.8% of cases. Patients with a medical history of cardiovascular diseases had more than two times increased odds to have a severe or critical disease. We also found the highest self-estimation of adherence to preventive measures was inversely correlated to serious cases and having an incomplete vaccination schema was strongly associated with complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We tried to provide evidence about the breakthrough infections to improve measures of prevention and control of COVID-19. Boosting immunity for vulnerable patients added to maintaining and promoting preventive measures are not only essential to prevent severe cases of breakthrough infections of COVID-19, but also other influenza-like diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07859-5","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T18:06:03Z","timestamp":1669658763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study"],"prefix":"10.1186","volume":"22","author":[{"given":"Sihem","family":"Ben Fredj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Ghammem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawel","family":"Zammit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihel","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouha","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Kachroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senda","family":"Rebai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsia","family":"Laadhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mizouni","family":"Ghodhbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihen","family":"Maatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassen","family":"Ghannem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"7859_CR1","unstructured":"World Health Organization. Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int. Accessed 4 Dec 2021"},{"key":"7859_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n494","volume":"372","author":"I Torjesen","year":"2021","unstructured":"Torjesen I. Covid-19 will become endemic but with decreased potency over time, scientists believe. BMJ. 2021;372: n494.","journal-title":"BMJ"},{"issue":"4","key":"7859_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/vaccines9040326","volume":"9","author":"T Hasan","year":"2021","unstructured":"Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination against SARS-CoV-2: a systematic review of existing strategies and guidelines. Vaccines. 2021;9(4):326.","journal-title":"Vaccines"},{"key":"7859_CR4","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). Our World Data. 2020. https:\/\/ourworldindata.org\/covid-vaccinations. Assessed 6 Dec 2021."},{"key":"7859_CR5","unstructured":"What are whole virus vaccines and how could they be used against COVID-19. https:\/\/www.gavi.org\/vaccineswork\/what-are-whole-virus-vaccines-and-how-could-they-be-used-against-covid-19. Assessed 5 Dec 2021."},{"issue":"1","key":"7859_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1377\/hlthaff.2020.02054","volume":"40","author":"AD Paltiel","year":"2021","unstructured":"Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical outcomes of A COVID-19 vaccine: implementation over efficacy. Health Affairs (Project Hope). 2021;40(1):42\u201352.","journal-title":"Health Affairs (Project Hope)"},{"issue":"10287","key":"7859_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819\u201329.","journal-title":"Lancet"},{"key":"7859_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: a test-negative case-control study. The BMJ. 2021;373: n1088.","journal-title":"The BMJ"},{"issue":"6","key":"7859_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.15985","volume":"4","author":"G Chodick","year":"2021","unstructured":"Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw Open. 2021;4(6): e2115985.","journal-title":"JAMA Netw Open"},{"issue":"23","key":"7859_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.15585\/mmwr.mm7023e2","volume":"70","author":"A Christie","year":"2021","unstructured":"Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine\u2014United States, September 6, 2020\u2013May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):858\u201364.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"7859_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc2104849","volume":"385","author":"EM White","year":"2021","unstructured":"White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-CoV-2 infection among mRNA-vaccinated and unvaccinated nursing home residents. New Engl J Med. 2021;385(5):474\u20136.","journal-title":"New Engl J Med."},{"issue":"5","key":"7859_CR12","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/S2468-2667(21)00055-4","volume":"6","author":"MS Graham","year":"2021","unstructured":"Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B117: an ecological study. Lancet Public Health. 2021;6(5):e335\u201345.","journal-title":"Lancet Public Health."},{"issue":"37","key":"7859_CR13","first-page":"1284","volume":"70","author":"HM Scobie","year":"2021","unstructured":"Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status\u201413 US jurisdictions, April 4\u2013July 17, 2021. MMWR. 2021;70(37):1284\u201390.","journal-title":"MMWR"},{"key":"7859_CR14","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7034e5","author":"JB Griffin","year":"2021","unstructured":"Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, Gounder P, Jarashow C, Balter S. SARS-CoV-2 infections and hospitalizations among persons aged \u226516 years, by vaccination status\u2014Los Angeles County, California, May 1\u2013July 25, 2021. MMWR. 2021. https:\/\/doi.org\/10.15585\/mmwr.mm7034e5.","journal-title":"MMWR"},{"key":"7859_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.27.21262356v1","author":"FP Havers","year":"2021","unstructured":"Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults \u226518 years\u2014COVID-NET, 13 states, January 1\u2013July 24, 2021. MedRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.08.27.21262356v1.","journal-title":"MedRxiv"},{"key":"7859_CR16","unstructured":"Ministry of Health. Coronavirus. Tunis, 2021. http:\/\/coronavirus.rns.tn\/. Assessed 8 Dec 2021."},{"key":"7859_CR17","unstructured":"Ministry of Health. Vaccination Strategy against covid-19. Tunis, 2021. http:\/\/www.santetunisie.rns.tn\/images\/strategie-vaccination-covid-19.pdf. Assessed 13 Nov 2021."},{"key":"7859_CR18","unstructured":"Ministry of Health. National Dashboard of coronavirus Vaccination. Tunis, 2021. https:\/\/evax.tn\/vaccinationOD.html. Assessed 13 Nov 2021."},{"key":"7859_CR19","unstructured":"National Institute of Statistics. Statistics of Tunisian population. Tunis, 2021. http:\/\/www.ins.tn\/statistiques\/111. Assessed 12 Oct 2021."},{"key":"7859_CR20","unstructured":"National Observatory of New and Emerging Diseases. Definition of COVID-19 cases in Tunisia. Tunis, 2020. https:\/\/www.onmne.tn\/?p=10305. Assessed 20 Jan 2022."},{"issue":"7","key":"7859_CR21","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2666-5247(21)00069-0","volume":"2","author":"P Olliaro","year":"2021","unstructured":"Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness\u2014the elephant (not) in the room. Lancet Microbe. 2021;2(7):e279\u201380.","journal-title":"Lancet Microbe"},{"issue":"4","key":"7859_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/v14040802","volume":"14","author":"V Stouten","year":"2022","unstructured":"Stouten V, Hubin P, Haarhuis F, van Loenhout JAF, Billuart M, Brondeel R, et al. Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium. Viruses. 2022;14(4):802.","journal-title":"Viruses"},{"issue":"4","key":"7859_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1681\/ASN.2021101395","volume":"33","author":"SM Brunelli","year":"2022","unstructured":"Brunelli SM, Sibbel S, Karpinski S, Marlowe G, Walker AG, Giullian J, et al. Comparative effectiveness of mRNA-based BNT162b2 vaccine versus adenovirus vector-based Ad26COV2S vaccine for the prevention of COVID-19 among dialysis patients. J Am Soc Nephrol. 2022;33(4):688\u201397.","journal-title":"J Am Soc Nephrol"},{"key":"7859_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab932","author":"W Bosch","year":"2021","unstructured":"Bosch W, Cowart JB, Bhakta S, Carter RE, Wadei HM, Shah SZ, et al. COVID-19 vaccine-breakthrough infections requiring hospitalization in mayo clinic florida through August 2021. Clin Infec Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab932.","journal-title":"Clin Infec Dis."},{"key":"7859_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1023","author":"AA Butt","year":"2021","unstructured":"Butt AA, Yan P, Shaikh OS, Mayr FB, Omer SB. Rate and risk factors for severe\/critical disease among fully vaccinated persons with breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a high-risk national population. Clin Infec Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab1023.","journal-title":"Clin Infec Dis."},{"issue":"1","key":"7859_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes, and impact. Nat Rev Immunol. 2022;22(1):57\u201365.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"7859_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13293-020-00304-9","volume":"11","author":"C Gebhard","year":"2020","unstructured":"Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.","journal-title":"Biol Sex Differ"},{"issue":"11","key":"7859_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241827","volume":"15","author":"I Lakbar","year":"2020","unstructured":"Lakbar I, Luque-Paz D, Mege J-L, Einav S, Leone M. COVID-19 gender susceptibility and outcomes: a systematic review. PLoSONE. 2020;15(11): e0241827.","journal-title":"PLoSONE"},{"issue":"7","key":"7859_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","volume":"20","author":"EP Scully","year":"2020","unstructured":"Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442\u20137.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"7859_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/heartjnl-2019-316378","volume":"108","author":"R Agca","year":"2022","unstructured":"Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022;108(1):73\u20139.","journal-title":"Heart"},{"issue":"7","key":"7859_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jacbts.2020.03.015","volume":"5","author":"RI Ja\u00e9n","year":"2020","unstructured":"Ja\u00e9n RI, Val-Blasco A, Prieto P, Gil-Fern\u00e1ndez M, Smani T, L\u00f3pez-Send\u00f3n JL, et al. Innate immune receptors, key actors in cardiovascular diseases. JACC Basic Transl Sci. 2020;5(7):735\u201349.","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"7859_CR32","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41418-022-01015-x","volume":"29","author":"Q Li","year":"2022","unstructured":"Li Q, Wang Y, Sun Q, Knopf J, Herrmann M, Lin L, et al. Immune response in COVID-19: what is next? Cell Death Differ. 2022;29(6):1107\u201322.","journal-title":"Cell Death Differ"},{"key":"7859_CR33","doi-asserted-by":"crossref","unstructured":"Kearns P, Siebert S, Willicombe M, Gaskell C, Kirkham A, Pirrie S, et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity\u2014the OCTAVE Trial. Rochester, NY: Social Science Research Network; 2021. Report No.: ID 3910058.","DOI":"10.2139\/ssrn.3910058"},{"issue":"1","key":"7859_CR34","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/S2666-5247(21)00306-2","volume":"3","author":"SY Wang","year":"2022","unstructured":"Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, et al. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B16172) variant era. Lancet Microbe. 2022;3(1):e4-5.","journal-title":"Lancet Microbe."},{"key":"7859_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12916-021-02038-w","volume":"19","author":"TNA Tran","year":"2021","unstructured":"Tran TNA, Wikle NB, Albert E, Inam H, Strong E, Brinda K, et al. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts. BMC Med. 2021;19:162.","journal-title":"BMC Med"},{"issue":"5","key":"7859_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102238","volume":"15","author":"A Bhattacharya","year":"2021","unstructured":"Bhattacharya A, Ranjan P, Ghosh T, Agarwal H, Seth S, Maher GT, et al. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: a single centre, cross-sectional analytical study from India. Diabetes Metab Syndr. 2021;15(5): 102238.","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"7859_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/vaccines10050755","volume":"10","author":"DJ Alcendor","year":"2022","unstructured":"Alcendor DJ, Matthews-Juarez P, Smoot D, Hildreth JE, Lamar K, et al. Breakthrough COVID-19 infections in the US: implications for prolonging the pandemic. Vaccines. 2022;10(5):755.","journal-title":"Vaccines"},{"key":"7859_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1943","volume":"374","author":"H Chung","year":"2021","unstructured":"Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. The BMJ. 2021;374: n1943.","journal-title":"The BMJ"},{"issue":"1","key":"7859_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010048","volume":"16","author":"L Li","year":"2022","unstructured":"Li L, Han Z-G, Qin P-Z, Liu W-H, Yang Z, Chen Z-Q, et al. Transmission and containment of the SARS-CoV-2 delta variant of concern in Guangzhou, China: a population-based study. PLoS Negl Trop Dis. 2022;16(1): e0010048.","journal-title":"PLoS Negl Trop Dis"},{"key":"7859_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","author":"JL Bernal","year":"2021","unstructured":"Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. New Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2108891.","journal-title":"New Engl J Med"},{"issue":"4","key":"7859_CR41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717\u201326.","journal-title":"Nat Med"},{"key":"7859_CR42","unstructured":"World Health Organization. The effects of virus variants on COVID-19 vaccines. Geneva, 2021. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-effects-of-virus-variants-on-covid-19-vaccines. Accessed 30 Aug 2022"},{"issue":"3","key":"7859_CR43","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/v14030624","volume":"14","author":"A Chouikha","year":"2022","unstructured":"Chouikha A, Fares W, Laamari A, Haddad-Boubaker S, Belaiba Z, Ghedira K, et al. Molecular epidemiology of SARS-CoV-2 in Tunisia (North Africa) through several successive waves of COVID-19. Viruses. 2022;14(3):624.","journal-title":"Viruses"},{"key":"7859_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1903879","author":"L Bian","year":"2021","unstructured":"Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, et al. Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021. https:\/\/doi.org\/10.1080\/14760584.2021.1903879.","journal-title":"Expert Rev Vaccines"},{"issue":"10309","key":"7859_CR45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet Lond Engl. 2021;398(10309):1407\u201316.","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"7859_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.2021.22898","volume":"327","author":"TA Bates","year":"2022","unstructured":"Bates TA, McBride SK, Winders B, Schoen D, Trautmann L, Curlin ME, et al. Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection. JAMA. 2022;327(2):179\u201381.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07859-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T18:08:48Z","timestamp":1669658928000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07859-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7859"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07859-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was conducted after approval of the Ethics Committee of the University Hospital Farhat Hached of Sousse (Tunisia). All participants were asked if they accept to participate to our study. All methods were carried out in accordance with relevant guidelines and regulations or declaration of Helsinki. Written informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"894"}}